New purines with antiplatelet activity

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Blood platelet aggregation plays a critical role in thrombosis and hemostasis.
• Developing novel inhibitors of platelet aggregation is crucial for managing cardiovascular diseases.

Purpose of the Study:

• To synthesize and characterize novel purine derivatives.
• To evaluate the anti-platelet aggregation activity of these compounds.
• To investigate the mechanism of action of potent inhibitors.

Main Methods:

• Synthesis of purine-2,6-diamines, N-(purin-2-yl)benzenecarboxamides, and N-(purin-2-yl)-2-furanecarboxamide derivatives.
• Assessment of inhibition of collagen-induced platelet aggregation using the Born test.
• Evaluation of anti-aggregating activity against adenosine diphosphate (ADP), platelet-activating factor (PAF), and adrenaline using specific inducers.

Main Results:

• Six compounds (6a, b, h, m, o, p) inhibited collagen-induced platelet aggregation with IC50 values between 3-10 µmol/L.
• Several compounds exhibited potent activity in the nanomolar to subnanomolar range against specific inducers.
• Compound 6b showed significant inhibition of ADP-induced aggregation (IC50 = 0.45 nM).
• Compound 7b displayed strong antagonism against adrenaline (IC50 = 1.8 nM) and PAF (IC50 = 1 nM).

Conclusions:

• The synthesized purine derivatives possess significant anti-platelet aggregation properties.
• Compounds 6b and 7b are highly potent inhibitors and warrant further investigation for antithrombotic potential.
• The study provides novel chemical entities for the development of anti-platelet therapies.